Journal of Hematology & Oncology

official impact factor 2.93

Open Access Highly Access Review

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

Christophe Frémin and Sylvain Meloche*

Journal of Hematology & Oncology 2010, 3:8 doi:10.1186/1756-8722-3-8

No comments have yet been made on this article.

Post a comment